A 55-year-old woman with myasthenia gravis presents with progressive muscle weakness and fatigability. Which anticholinesterase is the drug of choice for long-term symptomatic management?

Explanation

## Drug of Choice for Myasthenia Gravis **Key Point:** Pyridostigmine is the first-line anticholinesterase for chronic symptomatic management of myasthenia gravis because it has a longer duration of action (3–8 hours), better oral bioavailability, and a wider therapeutic window compared to other anticholinesterases. ### Mechanism in Myasthenia Gravis Myasthenia gravis is an autoimmune disorder with antibodies against nicotinic acetylcholine receptors at the neuromuscular junction. Anticholinesterases: - Inhibit acetylcholinesterase (AChE) - Increase acetylcholine (ACh) concentration at the NMJ - Enhance neuromuscular transmission despite reduced receptor numbers ### Comparative Pharmacology of Anticholinesterases | Property | Pyridostigmine | Edrophonium | Neostigmine | Physostigmine | |----------|---|---|---|---| | **Duration** | 3–8 hours | 5–10 minutes | 2–8 hours | 3–8 hours | | **Route** | Oral (preferred), IM, IV | IV only | IM, IV, oral | Topical, IM, IV | | **Onset** | 30–60 min (oral) | 30–60 seconds (IV) | 7–15 min (IM) | 3–8 min (IM) | | **CNS penetration** | Minimal (quaternary amine) | Minimal | Minimal | **Yes** (tertiary amine) | | **Muscarinic effects** | Mild | Minimal | Marked | Marked | | **DOC for MG** | **Yes** | Diagnostic only | Alternative | No | | **Use in MG** | Chronic management | Edrophonium test (diagnostic) | Acute exacerbation | Contraindicated | **High-Yield:** Pyridostigmine is preferred because: 1. **Longest duration** among oral agents → fewer dosing intervals 2. **Oral bioavailability** → suitable for chronic outpatient therapy 3. **Minimal muscarinic effects** → fewer GI side effects (quaternary amine does not cross BBB) 4. **Therapeutic window** → allows dose titration without CNS toxicity **Clinical Pearl:** Edrophonium (Tensilon) is used for **diagnostic testing** (Tensilon test) to confirm MG, not for chronic treatment. Physostigmine crosses the blood-brain barrier and can cause CNS cholinergic toxicity — contraindicated in MG. **Mnemonic:** **Pyridostigmine = Prolonged** — the "P" links to its prolonged duration, making it ideal for chronic MG management. **Warning:** Do not confuse edrophonium (diagnostic) with pyridostigmine (therapeutic). Edrophonium's short duration makes it unsuitable for chronic use. ### Dosing in MG - **Pyridostigmine:** 60 mg oral, 3–4 times daily; adjusted based on response - **Sustained-release formulation:** 180 mg once or twice daily (useful for nocturnal symptoms) - Muscarinic side effects (salivation, bronchospasm) managed with atropine or glycopyrrolate if needed